Published in Oncotarget on October 19, 2016
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Cancer statistics in China, 2015. CA Cancer J Clin (2016) 12.92
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56
Local force and geometry sensing regulate cell functions. Nat Rev Mol Cell Biol (2006) 11.29
Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer (2003) 6.65
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38
Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A (2010) 4.95
Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A (2010) 4.17
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Mechanotransduction gone awry. Nat Rev Mol Cell Biol (2009) 4.00
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Mechanical control of tissue and organ development. Development (2010) 3.18
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell (2013) 3.17
External forces control mitotic spindle positioning. Nat Cell Biol (2011) 3.13
E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A (2011) 2.61
Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol (2013) 2.58
The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A (2012) 2.51
Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem (2011) 2.47
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31
The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase. J Biol Chem (2010) 2.27
LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24
Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol (2007) 1.95
MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun (2010) 1.92
The Salvador/Warts/Hippo pathway controls regenerative tissue growth in Drosophila melanogaster. Dev Biol (2010) 1.50
AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene (2010) 1.40
Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell (2010) 1.40
YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett (2014) 1.36
Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology (2009) 1.32
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26
Basement membrane sliding and targeted adhesion remodels tissue boundaries during uterine-vulval attachment in Caenorhabditis elegans. Nat Cell Biol (2011) 1.20
NMR analysis of the alphaIIb beta3 cytoplasmic interaction suggests a mechanism for integrin regulation. Proc Natl Acad Sci U S A (2010) 1.16
Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun (2013) 1.12
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Role of beta1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology (1999) 1.10
Cadherin-17 interacts with α2β1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene (2013) 1.06
Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene (2011) 1.02
Specific residues within the alpha 2 integrin subunit cytoplasmic domain regulate migration and cell cycle progression via distinct MAPK pathways. J Biol Chem (2001) 0.99
Regulators of mammalian Hippo pathway in cancer. Biochim Biophys Acta (2012) 0.99
An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets (2012) 0.95
Structural basis for autoactivation of human Mst2 kinase and its regulation by RASSF5. Structure (2013) 0.95
Modulation of in vivo migratory function of alpha 2 beta 1 integrin in mouse liver. Mol Biol Cell (1997) 0.95
Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction. Exp Cell Res (2015) 0.92
Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain. FASEB J (2007) 0.92
Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. Oncogene (2011) 0.91
Platelet alpha2beta1 integrin activation: contribution of ligand internalization and the alpha2-cytoplasmic domain. Blood (2003) 0.90
Integrin VLA-2 (alpha2beta1) function in postextravasation movement of human rhabdomyosarcoma RD cells in the liver. Cancer Res (1996) 0.90
Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides. FASEB J (2014) 0.90
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene (2011) 0.89
Role of extracellular matrix and YAP/TAZ in cell fate determination. Cell Signal (2013) 0.86
An RGD motif present in cadherin 17 induces integrin activation and tumor growth. J Biol Chem (2014) 0.84
Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One (2011) 0.83
A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc Natl Acad Sci U S A (2014) 0.81
An alternative DNA damage pathway to apoptosis in hematological cancers. Nat Med (2014) 0.80
HNF1α and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem (2010) 0.80
α2β1 Integrin. Adv Exp Med Biol (2014) 0.78
Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression. Oncogenesis (2015) 0.78
miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS One (2014) 0.99
Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer. Cancer (2012) 0.91
Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study. Oncotarget (2015) 0.80
Genetic variation in C12orf51 is associated with prognosis of intestinal-type gastric cancer in a Chinese population. Biomed Pharmacother (2014) 0.77
The prognostic impacts of TEA domain (TEAD) transcription factor polymorphisms in Chinese hepatocellular carcinoma patients. Oncotarget (2017) 0.75
The prognostic impacts of TEA domain (TEAD) transcription factor polymorphisms in chinese hepatocellular carcinoma patients. Oncotarget (2017) 0.75